AI assistant
NovoCure Ltd — Director's Dealing 2018
Jun 5, 2018
31949_dirs_2018-06-04_ca758cb1-000e-443a-901c-f0cc26711c12.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NovoCure Ltd (NVCR)
CIK: 0001645113
Period of Report: 2017-05-31
Reporting Person: Burkoth William T. (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-31 | Options to Buy Ordinary Shares | $31.45 | A | 12345 | Acquired | 2028-05-31 | Ordinary Shares (12345) | Direct |
| 2018-05-31 | Restricted Stock Unit | $ | A | 6145 | Acquired | Ordinary Shares (6145) | Direct |
Footnotes
F1: Options to buy 12,345 ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.
F2: Each restricted stock unit represents the right to receive, at settlement, one (1) ordinary share.
F3: These restricted stock units are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2019 annual general meeting of shareholders.